MannKind Announces CFO Transition
March 26, 2024 16:05 ET
|
MannKind
MANNKIND ANNOUNCES CFO TRANSITION
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
March 26, 2024 02:00 ET
|
VALNEVA
Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the ...
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus Zika
March 26, 2024 02:00 ET
|
VALNEVA
Saint-Herblain (France), le 26 mars 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui l’initiation d’un essai de Phase 1 pour...
Vaccine Adjuvants Market to Reach $1.5Billion Globally, By 2032 at 4% CAGR: Allied Market Research
March 12, 2024 09:02 ET
|
Allied Analytics LLP
Wilmington, New Castle, Delaware, March 12, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Vaccine Adjuvants Market by Product Type (Immunostimulants and Vehicles...
Global Recombinant Vaccine Market Size To Exceed USD 24.9 Billion By 2032 | CAGR of 11.75%
March 11, 2024 06:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States, March 11, 2024 (GLOBE NEWSWIRE) -- The Global Recombinant Vaccine Market Size is to Grow from USD 8.2 Billion in 2022 to USD 24.9 Billion by 2032, at a Compound Annual...
ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination
March 06, 2024 15:30 ET
|
ACTG
ACTG at CROI: HepB-CPG Vaccine Outperforms Standard Hepatitis B Vaccine for HIV Patients with Previous Vaccination Failures
Vaccine Adjuvants Market projected to reach USD 5.6 Billion by 2030, growing at a CAGR of 13.1% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study
February 05, 2024 04:00 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 05, 2024 (GLOBE NEWSWIRE) -- According to a research report "Vaccine Adjuvants Market”, by Product Type (Aluminum Adjuvants, Emulsion Adjuvants, Pathogen Components, Saponin-Based...
Cytomegalovirus Infections Market to Exhibit Moderate Growth by 2032, Evaluates DelveInsight | Leading Companies - ModernaTX, Inc., Merck Sharp & Dohme LLC, GlaxoSmithKline, AlloVir
January 29, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytomegalovirus Infections Market to Exhibit Moderate Growth by 2032, Evaluates DelveInsight | Leading Companies - ModernaTX, Inc., Merck Sharp &...
Vaccine Adjuvants Market Set to Soar Past USD 2.90 Billion by 2030
January 25, 2024 11:00 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- According to SkyQuest's latest global research of the Vaccine Adjuvants Market, adoption of synthetic adjuvants, personalized medicine in vaccine...
Vaccine Adjuvants Industry Forecast to 2034: A $7.36 Billion Market Opportunity, Dominated by Merck & Co, Thermo Fisher Scientific, and Pacific GeneTech
January 24, 2024 14:18 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Adjuvants Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global vaccine...